Respiratory solutions provider VARON announced on Tuesday that it is expanding access to home oxygen concentrators.
The company said that this expansion is intended to help individuals with respiratory conditions maintain independence and an active lifestyle.
By providing flexible, user-friendly options, VARON ensures respiratory support is tailored to real-life needs, helping individuals breathe easier without limitations.
VARON offers a range of home and portable oxygen concentrators designed to fit different lifestyles. Its home oxygen concentrators are designed for long-term, stable oxygen support, while portable devices help users maintain active routines without sacrificing independence.
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer